Johnson & Johnson is scheduled to report Q3 2026 results on October 13, with the MedTech segment—representing roughly 36% of total revenue—under scrutiny for sequential improvement after Q2 sales of $8.93 billion (+4.5% YoY). Consensus estimates center near $8.78 billion, reflecting expectations of acceleration in Surgery, Vision, and Orthopedics offset by persistent pressure in Cardiovascular from Abiomed softness, electrophysiology competition, and China volume-based procurement impacts. Innovative Medicine strength has supported overall guidance (FY sales midpoint $101.1 billion), but MedTech margins and procedure volumes remain key variables priced into trader positioning ahead of the release.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-updateView resolved

Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong